AbbVie, Novartis, Bristol Myers Sue Illinois Over 340B Law
Three of the largest drugmakers filed separate Illinois suits in a week over a state law governing 340B discount pricing, widening a national legal fight over contract pharmacies.
AbbVie, Novartis and Bristol Myers Squibb each filed separate lawsuits in Illinois over the past week challenging a state law that regulates how drugmakers handle 340B discount pricing, extending an industry litigation campaign against contract pharmacy statutes into another state.
Three of the world's larger drugmakers have opened a new front in the long-running fight over the federal 340B drug discount program, this time in Illinois. AbbVie Inc. (NYSE: ABBV), Novartis AG (SWISS: NVS) and Bristol-Myers Squibb Co (NYSE: BMY) each filed separate lawsuits over the past week challenging an Illinois state law that seeks to regulate how pharmaceutical companies handle 340B, according to reporting by Endpoints News.
The filings are separate actions rather than a single coordinated complaint, which is the pattern the industry has followed elsewhere: each manufacturer brings its own case, on its own facts, against the same statute. That structure gives each company its own record on appeal and avoids the appearance of collective action, while producing the same practical result — a cluster of near-simultaneous challenges landing on the same court.
What 340B actually requires, and where the dispute starts
The 340B program obliges drug manufacturers that want their products covered by Medicaid and Medicare Part B to sell those products at steep statutory discounts to a defined set of safety-net providers: certain hospitals serving large low-income populations, federally qualified health centers, Ryan White clinics and other grantees. The discount is not optional. A manufacturer that refuses to offer it risks its access to the federal programs that account for a large share of US drug volume.
The friction is not over the discount itself. It is over who may physically dispense the discounted drug. Many 340B-covered entities do not run their own pharmacies, so they contract with outside pharmacies — including large retail chains and specialty dispensers — to fill prescriptions on their behalf. Manufacturers argue that the statute says nothing about contract pharmacies, that the arrangement has expanded far beyond anything Congress contemplated, and that duplicate discounts and diverted product are the predictable result. Over recent years, several large drugmakers moved to restrict how many contract pharmacies a covered entity can use, or to require claims-level data before honoring a discount.
States responded with legislation. A growing number have enacted laws that bar manufacturers from denying, restricting or conditioning 340B pricing on the use of a contract pharmacy, and some add reporting or notification duties. Illinois' statute sits in that family. The manufacturers' legal theory in these cases has generally rested on federal preemption — the argument that a state cannot rewrite the terms of a federal pricing program or a federal contract — alongside constitutional claims touching on the taking of property and interference with interstate commerce.
Why Illinois matters more than a single state usually would
Illinois is a large commercial market with a dense concentration of academic medical centers and disproportionate-share hospitals, the category of provider that has driven most of the growth in 340B volume. A state law that guarantees unlimited contract pharmacy access in that market therefore carries more dollars behind it than the same words would in a smaller state.
There is also the appellate map. Cases of this type have produced mixed results across federal circuits, and the more states that legislate, the more likely it becomes that conflicting rulings force the question upward. Bringing three separate suits in Illinois — quickly, and within days of each other — reads as an attempt to get the industry's arguments in front of a court before the statute's compliance obligations harden into practice.
For hospitals and clinics, the stakes run the other way. 340B savings are not earmarked; covered entities use the spread between the discounted acquisition price and what payers reimburse to fund charity care, clinic operations and service lines that do not pay for themselves. Restrictions on contract pharmacies cut that spread directly, which is why hospital associations have been the loudest supporters of state contract pharmacy laws.
The financial stakes behind the paperwork
None of the three companies has quantified an Illinois-specific exposure, and the lead does not put a figure on the statute's cost. What can be said is directional: 340B has become one of the largest sources of gross-to-net erosion in US pharmaceutical pricing, meaning the gap between a drug's list price and what the manufacturer actually collects. Products dispensed at retail through contract pharmacies — chronic-disease medicines, specialty immunology and oncology drugs — are exactly the categories where these three companies concentrate revenue.
None of the three companies has quantified an Illinois-specific exposure, and the lead does not put a figure on the statute's cost.
That is the commercial logic of the litigation. A win narrows the universe of pharmacies eligible to buy at 340B prices; a loss leaves manufacturers obliged to honor the discount at any pharmacy a covered entity designates, in every state that passes a law like Illinois'. Because compliance is effectively state-by-state, each new statute adds administrative cost even where the underlying discount is unchanged.
How the shares traded on the day
Litigation of this kind rarely moves large-cap pharma shares on the day it is filed, and Tuesday was no exception. As of the last trade at 20:00 GMT on 11 August 2026, AbbVie was at $249.93, up 0.79%, from a prior close of $247.97, trading in a day range of $247.18 to $250.76. Novartis was at $154.61, down 1.39% from a prior close of $156.79. Bristol Myers Squibb was the weakest of the three at $63.63, down 1.87% from $64.84, with a day range of $63.54 to $65.02.
The broad market was soft in the same session. The S&P 500 tracker was at $770.48, down 0.33%; the Nasdaq 100 tracker at $718.28, down 0.36%; and the Dow tracker at $537.28, down 0.32%. On that reading, AbbVie outperformed a down tape while the other two lagged it — a spread more plausibly explained by company-specific factors than by three separate 340B complaints in one state.
What to watch from here
The near-term questions are procedural. Whether the manufacturers seek preliminary injunctions to suspend the Illinois law while the cases proceed will indicate how urgent they consider the compliance deadlines. Whether the three cases are consolidated before a single judge will shape the pace. And whether Illinois' attorney general defends the statute aggressively — as officials in other states have — will determine how quickly a ruling arrives.
Beyond Illinois, the signal to track is legislative rather than judicial: each additional state contract pharmacy law raises the cost of the manufacturers' restriction strategy and increases the odds that Congress or the Supreme Court is eventually forced to settle what the 340B statute means by a pharmacy.
Key facts
- Filings: AbbVie, Novartis and Bristol Myers Squibb each filed separate suits in Illinois over the past week
- Target: An Illinois state law regulating how manufacturers handle 340B discount pricing
- Share prices (last trade 20:00 GMT, 11 Aug 2026): ABBV $249.93 (+0.79%); NVS $154.61 (-1.39%); BMY $63.63 (-1.87%)
- Market backdrop: S&P 500 (SPY) $770.48, -0.33%; Nasdaq 100 (QQQ) $718.28, -0.36%
Frequently asked questions
What is the 340B program?
340B is a federal drug pricing program that requires manufacturers to sell certain outpatient drugs at steep statutory discounts to safety-net providers such as disproportionate-share hospitals, federally qualified health centers and Ryan White clinics. Participation is effectively mandatory for drugmakers that want their products covered by Medicaid and Medicare Part B.
What is a contract pharmacy and why is it contested?
A contract pharmacy is an outside pharmacy that dispenses 340B-discounted drugs on behalf of a covered entity that lacks its own pharmacy. Manufacturers say the 340B statute never authorized the practice and that it has expanded far beyond congressional intent, inviting duplicate discounts and diversion. Hospitals say contract pharmacies are essential to reaching patients.
Which companies filed the Illinois lawsuits?
AbbVie, Novartis and Bristol Myers Squibb each filed a separate lawsuit in Illinois over the last week, according to Endpoints News. They are individual actions rather than one joint complaint, which gives each manufacturer its own factual record and its own path on appeal against the same state statute.
Did the lawsuits move the companies' share prices?
Not visibly. As of the last trade at 20:00 GMT on 11 August 2026, AbbVie rose 0.79% to $249.93, while Novartis fell 1.39% to $154.61 and Bristol Myers Squibb fell 1.87% to $63.63. The broad market was also lower, with the S&P 500 tracker down 0.33% on the day.
What legal arguments do drugmakers typically use against these state laws?
Manufacturers generally argue federal preemption — that a state cannot alter the terms of a federal pricing program — together with constitutional claims about property takings and interference with interstate commerce. Results have varied across federal appeals courts, which is one reason the industry keeps litigating each new state statute.
Why does this matter to hospitals and clinics?
340B savings are unrestricted revenue for covered entities: the spread between the discounted purchase price and payer reimbursement helps fund charity care and clinic services. Limits on contract pharmacy access reduce that spread directly, which is why hospital groups have pushed states to pass laws guaranteeing contract pharmacy participation.
Sources
Photo: cottonbro studio · Pexels Licence — source
